1-3 of 3
Najla H. Al Ali
Close
Sort by
Journal Articles

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Clinical Trials & Observations
Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3677–3679.
https://doi.org/10.1182/bloodadvances.2023009781
Published: 2023
Journal Articles

Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes

Grace A. Ward, Kathy L. McGraw, Farnoosh Abbas-Aghababazadeh, Benjamin S. Meyer, Amy F. McLemore, Nicole D. Vincelette, Nghi B. Lam, Amy L. Aldrich, Najla H. Al Ali, Eric Padron, Javier Pinilla-Ibarz, Erico Masala, Valeria Santini, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Joseph Johnson, Brooke L. Fridley, Alan F. List
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2216–2228.
https://doi.org/10.1182/bloodadvances.2020003475
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Clinical Trials & Observations
Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2866–2870.
https://doi.org/10.1182/bloodadvances.2020001482
Published: 2020
Includes: Supplemental data